We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

15 hedge funds and large institutions have $21.1M invested in Outlook Therapeutics in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
15
Holders Change
+15
Holders Change %
–
% of All Funds
0.4%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$7.71M
2
PA
Perceptive Advisors
New York
+$4.89M
3
CAM
Cormorant Asset Management
Massachusetts
+$3.83M
4
ACA
Avoro Capital Advisors
New York
+$1.74M
5
SFM
Sphera Funds Management
Israel
+$966K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$7.04M +$7.71M +12,931 New
PA
2
Perceptive Advisors
New York
$4.46M +$4.89M +8,205 New
CAM
3
Cormorant Asset Management
Massachusetts
$3.49M +$3.83M +6,420 New
ACA
4
Avoro Capital Advisors
New York
$1.59M +$1.74M +2,917 New
SFM
5
Sphera Funds Management
Israel
$881K +$966K +1,619 New
Marshall Wace
6
Marshall Wace
United Kingdom
$851K +$933K +1,564 New
ACP
7
Acuta Capital Partners
California
$828K +$907K +1,521 New
PC
8
PointState Capital
New York
$680K +$746K +1,250 New
JG
9
Jefferies Group
New York
$540K +$592K +992 New
Millennium Management
10
Millennium Management
New York
$300K +$329K +551 New
Hudson Bay Capital Management
11
Hudson Bay Capital Management
Connecticut
$213K +$233K +391 New
MIM
12
Monashee Investment Management
Massachusetts
$170K – – –
Morgan Stanley
13
Morgan Stanley
New York
$34K +$37.6K +63 New
UBS Group
14
UBS Group
Switzerland
$5K +$5.37K +9 New
TRCT
15
Tower Research Capital (TRC)
New York
$2K +$2.39K +4 New
Wells Fargo
16
Wells Fargo
California
– +$596 +1 New

OTLK Hedge Fund Activity: Q2 2016 in Review

15 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2016, worth a combined $21.1M.

Buyers outnumbered sellers: 15 funds opened new OTLK positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $7.71M.

  • 15 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2016, up from 0 in Q1 2016.
  • Funds reported $21.1M of Outlook Therapeutics stock for Q2 2016.
  • 15 funds opened new Outlook Therapeutics positions in Q2 2016 and 0 closed out, a net change of +15 holders.
  • The largest Outlook Therapeutics buyer in Q2 2016 was Sabby Management, an estimated $7.71M added.

Based on aggregated 13F filings for Q2 2016.